These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 24289277)

  • 1. Quantitative summaries of treatment effect estimates obtained with network meta-analysis of survival curves to inform decision-making.
    Cope S; Jansen JP
    BMC Med Res Methodol; 2013 Dec; 13():147. PubMed ID: 24289277
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multivariate network meta-analysis of survival function parameters.
    Cope S; Chan K; Jansen JP
    Res Synth Methods; 2020 May; 11(3):443-456. PubMed ID: 32125077
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Challenges of modelling approaches for network meta-analysis of time-to-event outcomes in the presence of non-proportional hazards to aid decision making: Application to a melanoma network.
    Freeman SC; Cooper NJ; Sutton AJ; Crowther MJ; Carpenter JR; Hawkins N
    Stat Methods Med Res; 2022 May; 31(5):839-861. PubMed ID: 35044255
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Using decision thresholds for ranking treatments in network meta-analysis results in more informative rankings.
    Brignardello-Petersen R; Johnston BC; Jadad AR; Tomlinson G
    J Clin Epidemiol; 2018 Jun; 98():62-69. PubMed ID: 29454030
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Comparison of Alternative Network Meta-Analysis Methods in the Presence of Nonproportional Hazards: A Case Study in First-Line Advanced or Metastatic Renal Cell Carcinoma.
    Cope S; Chan K; Campbell H; Chen J; Borrill J; May JR; Malcolm W; Branchoux S; Kupas K; Jansen JP
    Value Health; 2023 Apr; 26(4):465-476. PubMed ID: 36503035
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bayesian multivariate network meta-analysis model for the difference in restricted mean survival times.
    Tang X; Trinquart L
    Stat Med; 2022 Feb; 41(3):595-611. PubMed ID: 34883534
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nonproportional Hazards in Network Meta-Analysis: Efficient Strategies for Model Building and Analysis.
    Wiksten A; Hawkins N; Piepho HP; Gsteiger S
    Value Health; 2020 Jul; 23(7):918-927. PubMed ID: 32762994
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bias in identification of the best treatment in a Bayesian network meta-analysis for binary outcome: a simulation study.
    Kibret T; Richer D; Beyene J
    Clin Epidemiol; 2014; 6():451-60. PubMed ID: 25506247
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A simple method for combining binomial counts or proportions with hazard ratios for evidence synthesis of time-to-event data.
    Watkins C; Bennett I
    Res Synth Methods; 2018 Sep; 9(3):352-360. PubMed ID: 29707913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Degree irregularity and rank probability bias in network meta-analysis.
    Davies AL; Galla T
    Res Synth Methods; 2021 May; 12(3):316-332. PubMed ID: 32935913
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Log-Rank Test vs MaxCombo and Difference in Restricted Mean Survival Time Tests for Comparing Survival Under Nonproportional Hazards in Immuno-oncology Trials: A Systematic Review and Meta-analysis.
    Mukhopadhyay P; Ye J; Anderson KM; Roychoudhury S; Rubin EH; Halabi S; Chappell RJ
    JAMA Oncol; 2022 Sep; 8(9):1294-1300. PubMed ID: 35862037
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Empirical power comparison of statistical tests in contemporary phase III randomized controlled trials with time-to-event outcomes in oncology.
    Horiguchi M; Hassett MJ; Uno H
    Clin Trials; 2020 Dec; 17(6):597-606. PubMed ID: 32933339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjustment for reporting bias in network meta-analysis of antidepressant trials.
    Trinquart L; Chatellier G; Ravaud P
    BMC Med Res Methodol; 2012 Sep; 12():150. PubMed ID: 23016799
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves.
    Guyot P; Ades AE; Ouwens MJ; Welton NJ
    BMC Med Res Methodol; 2012 Feb; 12():9. PubMed ID: 22297116
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Leveraging Cumulative Network Meta-analysis and Value of Information Analysis to Understand the Evolving Value of Medical Research.
    Kim DD; Trikalinos TA; Wong JB
    Med Decis Making; 2019 Feb; 39(2):119-129. PubMed ID: 30678537
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modelling heterogeneity variances in multiple treatment comparison meta-analysis--are informative priors the better solution?
    Thorlund K; Thabane L; Mills EJ
    BMC Med Res Methodol; 2013 Jan; 13():2. PubMed ID: 23311298
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bayesian one-step IPD network meta-analysis of time-to-event data using Royston-Parmar models.
    Freeman SC; Carpenter JR
    Res Synth Methods; 2017 Dec; 8(4):451-464. PubMed ID: 28742955
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of reporting bias in network meta-analysis of antidepressant placebo-controlled trials.
    Trinquart L; Abbé A; Ravaud P
    PLoS One; 2012; 7(4):e35219. PubMed ID: 22536359
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.